 |
|
Thiazolidinediones and the Risk of Nontraumatic Fractures in Patients With Diabetes: In Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In their letter published in the January 9, 2006, issue of the ARCHIVES, Mascitelli and Pezzetta1 state that thiazolidinedione use has been shown to decrease hip and femoral neck bone mineral density (BMD)2 and suggest that this is an explanation for our report that adults with type 2 diabetes mellitus are at higher fracture risk compared with adults without diabetes in the Health, Aging, and Body Composition (Health ABC) Study.3 While we agree that thiazolidinedione use may be associated with bone loss, the prevalence of thiazolidinedione use was too low to account for the increased fracture risk associated with type 2 diabetes mellitus that we reported.3 The reference that Mascitelli and Pezzetta1 cite is also from the Health ABC Study,2 and only 11 (2%) of 566 participants with diabetes in our report used a thiazolidinedione at the start of the study in 1997-1998. In the first 4 years . . . [Full Text of this Article]
AUTHOR INFORMATION
Elsa S. Strotmeyer, PhD, MPH;
Ann V. Schwartz, PhD;
Anne B. Newman, MD, MPH
RELATED ARTICLES
Thiazolidinediones and the Risk of Nontraumatic Fractures in Patients With Diabetes
Luca Mascitelli and Francesca Pezzetta
Arch Intern Med. 2006;166(1):126.
EXTRACT
| FULL TEXT
Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black Adults: The Health, Aging, and Body Composition Study
Elsa S. Strotmeyer, Jane A. Cauley, Ann V. Schwartz, Michael C. Nevitt, Helaine E. Resnick, Douglas C. Bauer, Frances A. Tylavsky, Nathalie de Rekeneire, Tamara B. Harris, and Anne B. Newman
Arch Intern Med. 2005;165(14):1612-1617.
ABSTRACT
| FULL TEXT
|
